Intellectual Property Magazine
AIPPI 2021: Covid-19 bottlenecks
TheInternational Federation of Pharmaceutical Manufacturers & Associations’Komal Kalha says barriers to the Covid-19 vaccine are dose sharing, tradebarriers and country readiness, not IP
Catherine White - IPM
The proposed Trade-Related Aspects of IntellectualProperty Rights (TRIPs) Covid-19 patent waiver could be “a legal nightmare
forthe entire legal community... and changing the law is not easy, even if youneed to change it for emergency proposals” so
said the International Federationof Pharmaceutical Manufacturers & Associations’ (IFPMA) Komal Kalha, addingthat a waiver
could have “a lot of jurisdictional and legal issue concerns”.